Travaux scientifiques

Prof. Dr. Saadettin Kılıçkap

479 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Side Effect Management of Immune-related Hepatotoxicity Due to Immune Checkpoint Inhibitors

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000604 PMID 41972337 Source : OpenAlex

  2. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

    Cancers, 2026

    DOI 10.3390/cancers18121979 PMID 42352512 Texte intégral en libre accèsSource : OpenAlex

  3. Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16868-5 Texte intégral en libre accèsSource : OpenAlex

  4. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Source : OpenAlex

  5. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)

    Clinical & Translational Oncology, 2026

    DOI 10.1007/s12094-026-04494-3 PMID 42400766 Source : OpenAlex

  6. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

    Clinical Genitourinary Cancer, 2026

    DOI 10.1016/j.clgc.2026.102594 PMID 42349378 Source : OpenAlex

  7. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

    JCO Global Oncology, 2026

    DOI 10.1200/go-25-00234 PMID 41855443 Texte intégral en libre accèsSource : OpenAlex

  8. Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-61177-3 PMID 42414499 Texte intégral en libre accèsSource : OpenAlex

  9. Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1

    JTO Clinical and Research Reports, 2026

    DOI 10.1016/j.jtocrr.2026.101029 PMID 42529322 Texte intégral en libre accèsSource : OpenAlex

  10. Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions

    European Journal of Cancer Care, 2026

    DOI 10.48130/ejcc-0026-0010 Source : OpenAlex

  11. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group

    JCO Global Oncology, 2026

    DOI 10.1200/go-26-00317 PMID 42715501 Texte intégral en libre accèsSource : ORCID

  12. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020642 PMID 41598581 Texte intégral en libre accèsSource : ORCID

  13. Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients

    Scientific reports, 2026

    DOI 10.1038/s41598-026-50526-x PMID 42103792 Texte intégral en libre accèsSource : Europe PMC

  14. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

    Discover oncology, 2026

    DOI 10.1007/s12672-026-04705-x PMID 41721952 Texte intégral en libre accèsSource : Europe PMC

  15. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

    Scientific reports, 2026

    DOI 10.1038/s41598-026-48955-9 PMID 41981174 Texte intégral en libre accèsSource : Europe PMC

  16. Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer

    Expert review of anticancer therapy, 2026

    DOI 10.1080/14737140.2026.2615853 PMID 41511755 2 citations (Europe PMC) Source : ORCID

  17. Evaluation of the Cellsway Microfluidic CTC Enrichment and Identification Platform for CTC Detection in Metastatic NSCLC

    Biosensors, 2026

    DOI 10.3390/bios16010034 PMID 41590288 Texte intégral en libre accèsSource : ORCID

  18. Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy

    Cancer, 2026

    DOI 10.1002/cncr.70339 PMID 41808570 2 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  19. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026

    DOI 10.1007/s12094-026-04228-5 PMID 41670816 Source : Europe PMC

  20. Dermoscopic and Histopathological Features of Melanocytic Lesions in Melanoma Patients Undergoing Adjuvant Systemic Therapy

    Dermatology Practical & Conceptual, 2026

    DOI 10.5826/dpc.1601a5814 PMID 41912203 Texte intégral en libre accèsSource : ORCID

  21. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062353 PMID 41899277 Texte intégral en libre accèsSource : ORCID

  22. Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

    JAMA Oncology, 2026

    DOI 10.1001/jamaoncol.2026.0818 PMID 42060297 10 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  23. Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC).

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.8014 1 citation (OpenAlex) Source : OpenAlex

  24. 72P Cemiplimab monotherapy for first-line advanced NSCLC patients with PD-L1 expression ≥50%: 6-y outcomes of EMPOWER-Lung 1

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.106379 Texte intégral en libre accèsSource : OpenAlex

  25. Performance-based activities of daily living using the Londrina ADL protocol in non-small cell lung cancer: A prospective cross-sectional controlled study: Performance-based ADL in NSCLC

    Medicine, 2026

    DOI 10.1097/md.0000000000049995 PMID 42536590 Texte intégral en libre accèsSource : OpenAlex

  26. Comprehensive Evaluation of Exercise Capacity in Colorectal Cancer Survivors: The Interplay Between Hemodynamic, Vascular, and Muscular Determinants

    European Respiratory Journal, 2026

    DOI 10.1183/13993003.congress-2026.pa2699 Source : OpenAlex

  27. 636 A phase 2 study of Ateganosine in combination with ICI in patients with advanced non-small cell lung cancer resistant to prior ICI and chemotherapy: an exploratory analysis of LDH and survival

    Journal for ImmunoTherapy of Cancer, 2026

    DOI 10.1136/jitc-2026-sitc2026.0636 Texte intégral en libre accèsSource : OpenAlex

  28. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

    Cancer Investigation, 2025

    DOI 10.1080/07357907.2025.2595536 PMID 41347635 1 citation (Europe PMC) Source : OpenAlex

  29. Treatment outcomes of sunitinib and/or pazopanib in advanced alveolar soft part sarcoma: A Turkish Oncology Group (TOG) study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-29276-9 PMID 41315659 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Very deep prostate-specific antigen decline is associated with longer rPFS in patients with metastatic castration-sensitive prostate cancer

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251369037 PMID 40895017 Texte intégral en libre accèsSource : OpenAlex

  31. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

    Clinical Lung Cancer, 2025

    DOI 10.1016/j.cllc.2025.07.015 PMID 40813186 2 citations (Europe PMC) Source : OpenAlex

  32. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

    Journal of Thoracic Oncology, 2025

    DOI 10.1016/j.jtho.2025.03.033 PMID 40118215 36 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  33. Understanding of Clinical Trials Among Patients With Cancer and Their Relatives

    JAMA Network Open, 2025

    DOI 10.1001/jamanetworkopen.2024.57020 PMID 39874033 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%

    Cancer, 2025

    DOI 10.1002/cncr.35864 PMID 40323717 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  35. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach

    Cancers, 2025

    DOI 10.3390/cancers17020233 PMID 39858018 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  36. Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

    Frontiers in Immunology, 2025

    DOI 10.3389/fimmu.2025.1693295 PMID 41451229 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  37. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

    Medicina, 2025

    DOI 10.3390/medicina61040638 PMID 40282929 5 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  38. Significant response to [225Ac]Ac-DOTATATE therapy in a patient with small cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging, 2025

    DOI 10.1007/s00259-025-07105-5 PMID 39865179 3 citations (OpenAlex) Source : OpenAlex

  39. Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy

    Cells, 2025

    DOI 10.3390/cells14130971 PMID 40643492 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  40. First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials

    JTO Clinical and Research Reports, 2025

    DOI 10.1016/j.jtocrr.2025.100947 PMID 41869512 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  41. Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2025.2557678 PMID 40931603 Texte intégral en libre accèsSource : OpenAlex

  42. Evaluation of Dual-Task Performance and Respiratory Muscle Endurance in Patients with Lung Cancer.

    European Respiratory Journal, 2025

    DOI 10.1183/13993003.congress-2025.pa5970 Source : OpenAlex

  43. Investigation of Chronotropic Response and Exercise Intolerance in Colorectal Cancer Survivors

    DergiPark (Istanbul University), 2025

    Source : OpenAlex

  44. Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients

    Medical Science Monitor, 2024

    DOI 10.12659/msm.945752 PMID 39256975 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  45. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102077 PMID 38626660 2 citations (Europe PMC) Source : OpenAlex

  46. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

    Medicine, 2024

    DOI 10.1097/md.0000000000037972 PMID 38787994 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  47. Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer

    Medical Science Monitor, 2024

    DOI 10.12659/msm.946751 PMID 39690723 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  48. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 citations (Europe PMC) Source : OpenAlex

  49. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-56046-w PMID 38461209 16 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  50. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

    Journal of Immunotherapy, 2024

    DOI 10.1097/cji.0000000000000508 PMID 38333962 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex